HCPCS code J7517 – Mycophenolate mofetil

Key takeaways

HCPCS code J7517 covers mycophenolate mofetil, oral, 250 mg per unit, sits in the J7500-J7599 immunosuppressive range, and is active for 2026.

One billing unit equals one 250 mg dose, so a patient taking 1,000 mg daily needs 4 units per day.

Medicare Part B covers J7517 for post-transplant patients, and the standalone immunosuppressive benefit reaches only kidney recipients whose sole coverage is Medicare.

J7518 is a different drug and J7519 is the 10 mg injectable, so neither one is a strength variant of J7517.

Pabau supports structured HCPCS code entry and tracks each J7517 submission through to the remittance.

HCPCS code J7517: code details at a glance

J7517 sits in the J7500-J7599 immunosuppressive drug subsection of HCPCS Level II. The Centers for Medicare and Medicaid Services (CMS) maintains the code set and updates it quarterly. The code is active and valid for 2026.

Important disambiguation: Myfortic is mycophenolate sodium, which HCPCS lists as mycophenolic acid under J7518. It is a different drug and it is not billed under J7517. If your practice dispenses Myfortic, switch the code before you submit.

Drug overview: mycophenolate mofetil (CellCept)

Mycophenolate mofetil (MMF) is an immunosuppressant that inhibits the proliferation of T and B lymphocytes, which reduces the immune response that causes organ rejection. The FDA approved it for rejection prophylaxis after kidney, liver, and heart transplants. Both brand-name CellCept and generic MMF 250 mg oral capsules are billed under J7517.

The drug is dispensed orally in 250 mg capsules or 500 mg tablets. Because J7517 is built on the 250 mg unit, billers convert every dose size into 250 mg increments before counting claim units. The 500 mg tablet is common clinically, but the billing unit does not change.

Why HCPCS billing instead of a retail pharmacy claim?

Post-transplant immunosuppressants fall under Medicare Part B when a provider dispenses or supplies them, rather than a retail pharmacy. Retail pharmacy claims go through the Part D benefit instead. Provider-dispensed MMF billed to Part B uses J7517 on a CMS-1500 or 837P claim, not a pharmacy benefit claim.

Medicare Part B coverage for HCPCS code J7517

Medicare Part B covers J7517 for post-transplant patients who need ongoing immunosuppressive therapy. The criteria vary by transplant type and by how the patient is enrolled. Checking eligibility before the visit costs far less than appealing a denial after it.

Note on the 2023 kidney transplant benefit: The standalone immunosuppressive drug benefit came from the Consolidated Appropriations Act of 2021. It reaches kidney transplant recipients who lose Part A coverage after 36 months and hold Medicare as their only health insurance. Liver and heart transplant recipients are not covered under this benefit category. Verify the enrollment status before billing.

How to bill HCPCS code J7517: units and reporting

Each unit of J7517 equals 250 mg. Divide the total milligrams dispensed by 250 to get the unit count for the claim line. Unit errors cause more underpayments and overpayments on J7517 than any other mistake.

Unit calculation examples

Bill only the quantity actually dispensed, not the maximum prescribed dose. If the patient received 90 days of therapy, bill the units dispensed across that supply period.

On an 837P electronic claim, J7517 goes in the procedure code field and the calculated count goes in the quantity field. A superbill that records total mg dispensed lets billing staff work out the units without calling the dispensing clinician.

J7517 fee schedule and reimbursement rates

Medicare prices J7517 from the Average Sales Price (ASP) methodology, which CMS refreshes every quarter. Part B drugs are generally paid at ASP plus 6%. Pull the figure from the CMS ASP drug pricing files for the quarter the date of service falls in. The physician fee schedule lookup does not carry payment allowances for Part B drugs.

Rates move every quarter, so treat any dollar figure in a reference guide, including this one, as a baseline rather than a quote. The remittance advice after adjudication tells you what the payer allowed per unit and flags any downward adjustment.

Medicare Administrative Contractors (MACs) may apply local coverage determinations that change J7517 payment in specific regions. Check your MAC’s published drug fee schedule and its LCD database before you submit high-volume claims.

ICD-10 diagnosis codes paired with J7517

Every J7517 claim needs at least one ICD-10 code establishing the clinical reason for immunosuppressive therapy. Transplant status codes from the Z94 category are the primary pairings. Rejection codes from the T86 series may be required when the drug is managing an active rejection episode. The wider Z94 and T86 families are listed in our ICD-10-CM code index.

These pairings reflect the combinations reported across coding references. Verify each code against your MAC’s local coverage determination for the transplant type. Some MACs want the Z94 status code and the T86 complication code together when you bill rejection management. Standard maintenance therapy usually takes the Z94 status code on its own.

NDC reporting requirements for J7517

Most Medicaid programs and many commercial payers require National Drug Code (NDC) reporting alongside J7517. Medicare Part B does not universally require it for oral drugs. Confirm your MAC’s rule before submission, because payer requirements differ more on this field than on almost any other.

When NDC reporting is required, the NDC goes in the drug-quantity field of the CMS-1500 (Box 24) or in loop 2410 of the 837P. Format it as 11 digits with no dashes, in 5-4-2 order for the manufacturer, product, and package codes. The unit of measure qualifier is required too.

Common NDC formats for mycophenolate mofetil products

Always take the NDC from the package you dispensed, not from a reference guide. Generic manufacturers change package NDCs, and an NDC that does not match the dispensed product is a compliance risk.

Applicable modifiers for J7517

Modifiers add specificity to J7517 claims, and certain payers or coverage scenarios require them. Using the wrong modifier, or leaving out a required one, is one of the fastest paths to a denial.

A note on the JW modifier (drug wastage): JW exists for injectable drugs where a vial is opened but not fully used. CMS ties that policy to single-dose vials. Oral capsules are dispensed in exact quantities, so JW does not normally apply to J7517. Check with your MAC before appending it to an oral drug J-code.

Documentation requirements and common billing errors

Code lookup pages describe what J7517 is. The five errors below are the ones that stop a J7517 claim from being paid, and each maps to a field a biller controls.

Top 5 J7517 billing errors

• Wrong unit count. Billing 1 unit for a 1,000 mg daily dose underpays by 75%, because the correct figure is 4 units. Billing 4 units for a 250 mg dose overstates the quantity. Divide total mg dispensed by 250 every time.
• Missing transplant documentation. The medical record must carry the transplant date, the transplant type, and the treating provider’s order for MMF. Leave any one of them out and the claim draws a medical necessity denial.
• Incorrect or absent ICD-10 code. A generic Z-code with no specific transplant status is a pairing mismatch. So is a T86 rejection code with no Z94 status code beside it. Most claims editors flag both automatically.
• Missing NDC when required. Medicaid claims without NDC reporting are usually rejected at the clearinghouse, so they never reach adjudication. Know which payers in your mix require an NDC before batch submission.
• Billing Myfortic under J7517. Myfortic is mycophenolate sodium, coded as mycophenolic acid under J7518. Putting it on a J7517 line is an incorrect code assignment that repeats badly under audit.

A pre-submission checklist catches these before the payer does. Build it around the three fields that fail most often on this code. Those are the unit count, the Z94 diagnosis, and the NDC where the payer requires one.

When a J7517 claim is denied, the remittance advice carries the reason code. Denial management for immunosuppressive drug claims usually means pulling the dispensing record, confirming the transplant documentation is in the chart, and resubmitting a corrected claim. Getting the units, the diagnosis, and the NDC right the first time avoids that cycle.

Related HCPCS immunosuppressive drug codes

J7517 sits inside the J7500-J7599 immunosuppressive range. Adjacent codes share a drug name without sharing a billing unit, and that is where miscoding starts. The CMS HCPCS quarterly update file carries the current long descriptors, and the AAPC HCPCS lookup gives a searchable index.

Sorted by code number, the units look arbitrary. Grouped by drug, the pattern shows where the sibling codes actually diverge.

J7517 and J7518 are different drugs, not two strengths of one drug. J7518 covers mycophenolic acid, the delayed-release salt sold as Myfortic. J7519 is the injectable form of mycophenolate mofetil, and its unit is 10 mg rather than 250 mg. Picking the wrong sibling is common when a patient’s formulation changes mid-course.

How claims management software keeps J7517 units and documentation together

A practice billing J7517 today usually works across three systems. The dispensing record sits in one place, the transplant documentation in the chart, and the claim in a billing tool or a clearinghouse portal. Unit counts get retyped somewhere along that path.

Practice management software like Pabau holds the encounter, the documentation, and the claim in one patient record. Codes go in through structured fields rather than free text, so the J7517 line carries the unit count and diagnosis you recorded at the visit. Pabau’s medical claims management then tracks each submission through to the remittance.

The result is fewer numbers retyped between systems and a shorter trail to follow when a payer questions a J7517 line. Your billers work from the record instead of rebuilding it.

Keep HCPCS drug claims tied to the record

Pabau gives specialty and transplant practices structured HCPCS code entry, dispensed-quantity records, and submission tracking for complex drug codes like J7517.

Book a demo

Conclusion

J7517 is a narrow code with a short list of ways to get it wrong. The unit math, the Z94 diagnosis, the transplant documentation, and the NDC account for most of the denials the code attracts.

Fixing those four before submission, rather than after a remittance comes back short, is where transplant and specialty practices protect their margin on immunosuppressive billing. It also cuts the appeals your billing team has to write.

Book a demo to see how Pabau handles HCPCS claim entry and submission tracking for specialty practices.

Continue your research

Need to see how claims move through a clearinghouse? Medical claims clearinghouse guide explains the adjudication pathway from submission to payment posting.

Want fewer rejections on complex drug codes? Claim.MD clearinghouse overview covers how electronic claims validation catches errors before they reach the payer.

Not sure what a clean claim has to contain? What makes a clean claim lists the fields payers check first on a drug line.

Building a superbill for dispensed drugs? Superbill guide shows what to record so unit counts can be calculated later.

Wondering where J7517 errors sit in the wider billing process? Revenue cycle management fundamentals walks through the end-to-end claim lifecycle for specialty practices.

Frequently asked questions